Myriad Genetics price target raised to $29 from $25 at Guggenheim

Guggenheim analyst Subbu Nambi raised the firm’s price target on Myriad Genetics to $29 from $25 and keeps a Buy rating on the shares following what the firm calls “another solid beat and raise” report. The firm continues to believe the outlook for long-term revenue growth and profitability is attractive, the analyst tells investors post earnings.